[The efficacy and tolerance of Bay-o-9867 (ciprofloxacin) in the treatment of infections of the urinary tract and of the lower respiratory tract].
A clinical trial was performed to evaluate efficacy and tolerability of Bay-o-9867 in the treatment of UTI and LRTI. 40 patients were admitted to the study: 27 affected with LRTI, mainly exacerbations of COPD, and 15 affected with UTI. Two patients were affected concomitantly with a UTI and LRTI. The patients were treated with Bay-o-9867 (ciprofloxacin) administered orally at a daily dosage of 500 mg (250 q 12 h) in 30 patients and of 1000 mg (500 q 12 h) in 10 patients, depending on the severity of infection. Clinical results were extremely favourable as complete clinical resolution of infective episode was achieved in 38 patients (15/15 in UTI patients; 25/27 in LRTI patients), whereas improvement was achieved in 2 (in LRTI). Overall clinical efficacy was therefore successful in 100% of cases. Concerning bacteriological results, 38 pathogens were isolated from infective sites before starting treatment, and all were eradicated (eradication rate: 100%). Tolerability was assessed as good: no adverse event was observed.
Quartieri
F
F
I Divisione di Medicina e Allergologia, USL 12, Pisa.
Bolognesi
S
S
Sconosciuto
F
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy*; D002939:Ciprofloxacin / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002939:Ciprofloxacin
Efficacia e tollerabilità di Bay-o-9867 (ciprofloxacina) nel trattamento di infezioni delle vie urinarie e delle basse vie respiratorie.